Merck & Co., Inc. (MRK) vs NOVAVAX INC (NVAX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | MRK | NVAX |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $65.01B | $1.12B |
| Revenue growth (YoY) | ▲ 1.3% | ▲ 64.7% |
| Net income | $18.25B | $440.3M |
| Gross margin | 74.8% | 93.5% |
| Diluted EPS | $7.28 | $2.58 |
| Insider net (6 mo) | −101.8K sh • 9 sells • 0 buys | +113.3K sh • 0 sells • 0 buys |
| Institutional owners | 67 | 43 |
| Institutional value held | $177.99B | $835.44M |
| Next earnings (est.) | Feb 2, 2027 | Around Feb 25, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are managed principally on a product basis. Read more →
About NOVAVAX INC (NVAX)
Novavax, Inc. is a vaccine company, incorporated in Delaware in 1987, that develops vaccines using a recombinant protein-based nanoparticle technology and its proprietary Matrix-M adjuvant. Read more →
Source: SEC EDGAR.